BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34180759)

  • 1. Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).
    Wang W; Gan Z; Liu Q; Yan S; Mulati R; Wang Y
    Bioengineered; 2021 Dec; 12(1):2957-2969. PubMed ID: 34180759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
    Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
    Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
    Wu W; Yu LH; Ma B; Xu MJ
    PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
    Long Q; Sun J; Lv J; Liang Y; Li H; Li X
    Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
    Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
    Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
    Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
    Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
    Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive profiling of circRNAs and the tumor suppressor function of circHIPK3 in clear cell renal carcinoma.
    Li H; Heng B; Ouyang P; Xie X; Zhang T; Chen G; Chen Z; Cheang K; Lai C
    J Mol Histol; 2020 Jun; 51(3):317-327. PubMed ID: 32409849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma.
    Struckmann K; Mertz K; Steu S; Storz M; Staller P; Krek W; Schraml P; Moch H
    J Pathol; 2008 Mar; 214(4):464-71. PubMed ID: 18189328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocyte Elevated Gene 1 (AEG-1) Acts as a Promoter Gene in Clear Cell Renal Cell Carcinoma Cell Growth and Metastasis.
    Yu DP; Zhou Y
    Med Sci Monit; 2018 Nov; 24():8213-8223. PubMed ID: 30431025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
    Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
    Oncotarget; 2015 Jan; 6(2):1020-30. PubMed ID: 25544759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.